p21WAF1 immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 208-215

  Barbareschi, M ^a,f   Caffo, O ^a   Doglioni, C ^b   Fina, P ^c   Marchetti, A ^d   Buttitta, F ^d   Leek, R ^e   Morelli, L ^a   Leonardi, E ^a   Bevilacqua, G ^d   Dalla Palma, P ^a   Harris, A L ^e  

^a SANTA CHIARA HOSPITAL   (Italy)

^b Hospital of Belluno   (Italy)

^c GSK   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f Anatomia Patalogica   (Italy)

Author keywords

Inhibitor of cyclin dependent kinase; p21 WAF1 CIP1; p53

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ESTROGEN RECEPTOR; KI 67 ANTIGEN; NUCLEAR PROTEIN; PROTEIN P53; TUMOR PROTEIN; PROTEIN P21;

ARTICLE; BREAST TUMOR; CHEMISTRY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; SURVIVAL; TUMOR SUPPRESSOR GENE; BREAST CARCINOMA; CANCER SURVIVAL; CELL NUCLEUS; GENE MUTATION; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MYOEPITHELIUM CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE-FREE SURVIVAL; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029665943     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.339     Document Type: Article

References (42)

1. ANSARI B, DOVER R, GILLMORE GP AND HALL PA. (1993). Expression of the nuclear membrane statin in cycling cells. J. Pathol., 169, 391-396.
2. AZZOPARDI J. (1979). Problems in Breast Pathology. Saunders: London.
3. BARBARESCHI M, GIRLANDO S, MAURI MF, FORTI S, CHHER C, MAURI FA, TOGNI R, DALLA PALMA P AND DOGLIONI C. (1994). Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am. J. Clin. Pathol., 102, 171-175.
4. BURSCH W, OBERHAMMER F, JIRTLE RL, ASKARI M, SEDIVY R, GRASL-KRAUPP B, PURCHIO AF AND SCHULTE-HERMANN R. (1993). Transforming growth factor beta 1 as a signal for induction of cell death by apoptosis. Br. J. Cancer, 67, 531-536.
5. DATTO MB, LI Y, PANUS JF, HOWE DJ, XIONG Y AND WANG XF. (1995). Transforming growth factor B induces the cyclin-dependent kinas inhibitor p21 through a p53-independent mechanism. Proc. Natl Acad. Sci. USA, 92, 5545-5549.
6. DEI TOS AP, DOGLIONI C, BARBARESCHI M, LAURINO L AND FLETCHER CDM. (1993). p53 expression in soft tissue lesions. Histopathology, 22, 45-50.
7. DEI TOS APD, MAESTRO R, DOGLIONI C, GASPAROTTO D, BOIOCCHI M, LAURINO L AND FLETCHER CDM. (1994). Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am. J. Pathol., 145, 11-17.
8. DOGLIONI C, DEI TOS AP, LAURINO L, MOSCHIN A, BARBARESCHI M AND VIALE G. (1994). The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathologic correlates, with particular reference to estrogen receptor status. Virchows Arch. A, 424, 47-51.
9. DOGLIONI C, PELOSIO P, LAURINO L, MACRI E AND BARBARESCHI M. (1996). p21/WAF1/CIP1 expression in normal mucosa, adenomas and adenocarcinomas of the colon: its relationship with differentiation. J. Pathol. (in press).
10. EL-DEIRY WS, TOKINO T, VELCULESCU VE, LEVY DB, PARSON R, TRENT JM, LIN D, MERCER E, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
11. 1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
12. EL-DEIRY WS, TOKINO T, WALDMAN T, OLINER JD, VELCULESCU VE, BURREL M, HILL DE, HEALY E, REES JL, HAMILTON SR, KINZLER KW AND VOGELSTEIN B. (1995). Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919.
13. ELSTON CW AND ELLIS IO. (1991). Pathological prognostic factors in breast cancer. The evaluation of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology, 19, 403-410.
14. FERGUSON DJ AND ANDERSON TJ. (1981). Morphological evaluation of cell turnover in relation to the menstrual cycle in the 'resting' human breast. Br. J. Cancer, 44, 177-181.
15. GASPARINI G, BARBARESCHI M, DOGLIONI C, DALLA PALMA P, MAURI FA, BORACCHI P, BEVILACQUA P, CAFFO O, MORELLI L, VERDERIO L, PEZZELLA F AND HARRIS AL. (1995). Expression of Bcl2 protein predicts efficacy of adjuvant treatment in operable breast cancer. Clin. Cancer Res., 1, 189-198.
16. GOING JJ, ANDERSON TJ, BATTESBY S AND MACINTYRE CCA. (1988). Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am. J. Pathol., 130, 193-204.
17. GORSCH SM, MEMOLI VA, STUKEL TA, GOLD LI AND ARRICK BA. (1992). Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res., 52, 6949-6952.
18. HALEVY O, NOVITCH BG, SPICER DB, SKAPEK SX, RHEE J, HANNON GJ, BEACH D AND LASSAR AB. (1995). Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science, 267, 1018-1021.
19. 1 cyclin-dependent kinases. Cell, 75, 805-816.
20. HOLLAND R, PETERSE JL, MILLIS RR, EUSEBI V, FAVERLY D AND VAN DE VIJVER MJ AND ZAFRANI B. (1994). Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Pathol., 1, 167-180.
21. JIANG H, LIN J, SU ZZ, COLLART FR, HUBERMAN E AND FISHER PB. (1994). Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogens, 9, 3397-3406.
22. JOHNSON M, DIMITROV D, VOJTA PJ, BARRETT JC, NODA A, PEREIRA-SMITH OM AND SMITH JR. (1994). Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 mRNA in human cells. Mol. Carcinogenesis, 11, 59-64.
23. LAN HY, MU W, NIKOLIC-PETERSON DJ AND ATKINS RC. (1995). A novel, simple, reliable and sensitive method for multiple immunoenyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J. Histochem. Cytochem., 43, 97-102.
24. LEVINE DS AND HAGGITT RC. (1992). Colon. In Histology for Pathologists, Sternberg SS (ed.), pp. 573-591. Raven Press: New York.
25. MARCHETTI A, BUTTITTA F, PELLEGRINI S, DIELLA F, CAMPANI D, CECCHETTI D, MERLO G, CALLAHAN R AND BISTOCCHI M. (1993). p53 mutations and histological type of invasive breast carcinoma. Cancer Res., 53, 4665-4669.
26. MARCHETTI A, BUTTITTA F, PELLEGRINI S, LORI A, BERTACCA G AND BEVI-LACQUA G. (1995). Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinomas: a polymorphism at codon 31. Int. J. Oncol., 6, 187-189.
27. MARCHETTI A, DOGLIONI C, BARBARESCHI M, BUTTITTA F, PELLEGRINI S, CHELLA A, ANGELETTI CA, DALLA PALMA P AND BEVILACQUA G. (1996). p21 mRNA and protein expression in non-small cell lung carcinomas: evidence of p53 independent expression and association with tumoral differentiation. Oncogene, (in press March 1996).
28. MAURI FA, VERONESE S, FRIGO B, GIRLANDO S, LOSI L, DALLA PALMA P AND BARBARESCHI M. (1994). ER1D5 and H222 (ERICA) antibodies to human estrogen receptor protein in breast carcinomas: a result of a multicentric comparative study. Appl. Immunohistochem., 2, 157-163.
29. MICHIELI P, CHEDID M, LIN D, PIERCE JH, MERCER WE AND GIVOL D. (1994). Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54, 3391-3395.
30. NODA A, NING Y, VENABLE SF, PEREIRA-SMITH OM AND SMITH JR. (1994). Clonation of senescent cell-derived inhibitors of DNA sysntesis using an expression screen. Exp. Cell. Res., 211, 90-98.
31. 0 phase, in human breast cancer tissues. Appl. Immunohistochem., 2, 248-253.
32. PARKER SB, EICHELE G, ZHANG P, RAWLS A, SANDS AT, BRADLEY A, OLSON EN, HAPER JW AND ELLEDGE SJ. (1995). p53-independent expression of p21/CIP1 in muscle and other terminally differentiating cells. Science, 267, 1024-1027.
33. SABOURIN JC, MARTIN A, BARUCH J, TRUC JB AND GOMPEL A AND POITUT P. (1994). bcl-2 expression in normal breast tissue during menstrual cycle. Int. J. Cancer, 59, 1-6.
34. SHEIKH MS, LI SX, SHAO ZM, ORDONEZ JV AND FONTANA JA. (1994). Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene, 9, 3407-3414.
35. SHEIKH MS, ROCHEFORT H AND GARCIA M. (1995). Over-expression of p21 (WAF1/CIP1) induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines.
36. SHIOHARA M, ELDEIRY WS, WADA M, NAKAMAKI, TAKEUCHI S, YANG R, CHEN DL, VOGELSTEIN B AND KOEFFLER HP. (1994). Absence of WAF1 mutations in a variety of human malinancies. Blood, 11, 3781-3784.
37. SINICROPE FA, RUAN SB, CLEARY KR, STEPHENS LC, LEE JJ AND LEVIN B. (1995). bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res., 55, 237-241.
38. STEINMAN RA, HOFFMAN B, IRO A, GUILLOUF C, LIEBERMANN DA AND EL-HOUSEINI MEE. (1994). Induction of p21 (WAF1/CIP1) during differentiation. Oncogene, 9 3389-3396.
39. TAHARA H, SATO E, NODA A AND IDE T. (1995). Increase in expression level of p21/sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblast. Oncogene, 10, 835-840.
40. VERONESE S, BARBARESCHI M, MORELLI L, ALDOVINI D, MAURI FA, CAFFO O, GAMBACORTA M AND DALLA PALMA. (1995). P. Predictive value of ER1D5 antibody immunostaining in breast cancer. A paraffin-based retrospective study of 257 cases. Appl. Immunohistochem., 3, 85-90.
41. XIONG Y, HANNON GJ, ZHANG H, CASSO D, KOBAYASHI R AND BEACH D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-707.
42. ZHANG W, GRASSO L, MCCLAIN GD, GAMBEL AM, CHA Y, TRAVALI S, DEISSEROTH AB AND MERCER WE. (1995). p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55, 668-674.